(19)
(11) EP 3 585 892 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.07.2022 Bulletin 2022/28

(45) Mention of the grant of the patent:
01.06.2022 Bulletin 2022/22

(21) Application number: 18711737.9

(22) Date of filing: 27.02.2018
(51) International Patent Classification (IPC): 
C12N 15/10(2006.01)
C12P 19/34(2006.01)
 C07H 1/06(2006.01)
(52) Cooperative Patent Classification (CPC):
C12N 15/1006; C12N 15/1017; C07H 21/04; C12Y 201/03003
(86) International application number:
PCT/US2018/019978
(87) International publication number:
WO 2018/157141 (30.08.2018 Gazette 2018/35)

(54)

METHODS FOR PURIFICATION OF MESSENGER RNA

VERFAHREN ZUR REINIGUNG VON MESSENGER-RNA

PROCÉDÉS DE PURIFICATION D'ARN MESSAGER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD TN

(30) Priority: 27.02.2017 US 201762463981 P

(43) Date of publication of application:
01.01.2020 Bulletin 2020/01

(60) Divisional application:
22151272.6 / 4008783

(73) Proprietor: Translate Bio, Inc.
Waltham, MA 02451 (US)

(72) Inventors:
  • DEROSA, Frank
    Lexington, MA 02421 (US)
  • HEARTLEIN, Michael
    Lexington, MA 02421 (US)
  • ABYSALH, Jonathan
    Lexington, MA 02421 (US)
  • KARVE, Shrirang
    Lexington, MA 02421 (US)
  • DIAS, Anusha
    Lexington, MA 02421 (US)
  • CRAWFORD, Daniel
    Lexington, MA 02421 (US)

(74) Representative: Elkington and Fife LLP 
Thavies Inn House 3-4 Holborn Circus
London EC1N 2HA
London EC1N 2HA (GB)


(56) References cited: : 
WO-A1-2014/144767
WO-A1-2016/193206
 WO-A1-2015/164773
   
  • KATALIN KARIKÓ ET AL: "Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, GB, vol. 39, no. 21, 1 November 2011 (2011-11-01), pages e142-1, XP002696190, ISSN: 1362-4962, DOI: 10.1093/NAR/GKR695 [retrieved on 2011-09-02]
  • UGUR SAHIN ET AL: "mRNA-based therapeutics - developing a new class of drugs", NATURE REVIEWS DRUG DISCOVERY, vol. 13, no. 10, 19 September 2014 (2014-09-19), pages 759-780, XP055159205, ISSN: 1474-1776, DOI: 10.1038/nrd4278
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).